iRhythm Technologies (IRTC) Stock Price, News & Analysis

Company Overview

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $145.63 to $153.32
• 50-Day Range: $99.48 to $154.71
• 52-Week Range: $55.92 to $157.13
• Volume: 475,108 shs
• Average Volume: 482,096 shs
• Market Capitalization: $4.66 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $138.60
• Consensus Rating: Moderate Buy

iRhythm Technologies Stock Analysis - MarketRank™

iRhythm Technologies scored higher than 21% of companies evaluated by MarketBeat, and ranked 868th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

iRhythm Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

iRhythm Technologies has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for iRhythm Technologies are expected to grow in the coming year, from ($1.98) to ($1.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of iRhythm Technologies is -46.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of iRhythm Technologies is -46.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

iRhythm Technologies has a P/B Ratio of 50.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.17% of the float of iRhythm Technologies has been sold short.

Short Interest Ratio / Days to Cover

iRhythm Technologies has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in iRhythm Technologies has recently increased by 5.31%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iRhythm Technologies does not currently pay a dividend.

Dividend Growth

iRhythm Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.17% of the float of iRhythm Technologies has been sold short.

Short Interest Ratio / Days to Cover

iRhythm Technologies has a short interest ratio ("days to cover") of 5.4.

Change versus previous month

Short interest in iRhythm Technologies has recently increased by 5.31%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.71

News Sentiment

iRhythm Technologies has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for iRhythm Technologies this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for IRTC on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, iRhythm Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $590,400.00 in company stock.

Percentage Held by Insiders

Only 0.68% of the stock of iRhythm Technologies is held by insiders.

IRTC Stock Analysis - Frequently Asked Questions

How have IRTC shares performed this year?

iRhythm Technologies' stock was trading at $90.17 on January 1st, 2025. Since then, IRTC stock has increased by 61.9% and is now trading at $146.0070.
View the best growth stocks for 2025 here.

How were iRhythm Technologies' earnings last quarter?

iRhythm Technologies (NASDAQ:IRTC) announced its earnings results on Thursday, May, 1st. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.89) by $0.06. The company's revenue was up 20.3% compared to the same quarter last year.
Read the conference call transcript.

When did iRhythm Technologies IPO?

iRhythm Technologies (IRTC) raised $76 million in an IPO on Thursday, October 20th 2016. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

How do I buy shares of iRhythm Technologies?

Shares of IRTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of iRhythm Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iRhythm Technologies investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/01/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:IRTC
• CIK: 1388658
• Web: www.irhythmtech.com
• Phone: (415) 632-5700
• Fax: N/A
• Employees: 2,000
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $138.60
• High Stock Price Target: $167.00
• Low Stock Price Target: $100.00
• Potential Upside/Downside: -5.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$113.29 million
• Net Margins: -15.90%
• Pretax Margin: -15.70%
• Return on Equity: -101.04%
• Return on Assets: -9.55%

Debt

• Debt-to-Equity Ratio: 7.47
• Current Ratio: 5.71
• Quick Ratio: 5.58

Sales & Book Value

• Annual Sales: $591.84 million
• Price / Sales: 7.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.90 per share
• Price / Book: 50.47

Miscellaneous

• Outstanding Shares: 31,920,000
• Free Float: 31,708,000
• Market Cap: $4.67 billion
• Optionable: Optionable
• Beta: 1.40